The first examples of ilexgenin A hybrids as a new class of multi-potent, anti-platelet agents
摘要:
Seventeen novel ilexgenin A hybrids (IA-aspirin) and (IA-NO), as donor hybrids (IA-NO will release NO in vivo and function as NO donor), were designed and synthesized in order to develop new multi-targeting agents for the treatment of platelet disorders. Their in vitro activities against ADP, AA and thrombin were evaluated. As a result, IA hybrids achieved substantial increases in the three tested pathways compared with IA. Encouragingly, the most potent hybrid compounds 6d and 14d displayed about 8-fold higher potency than aspirin, and 3-fold higher potency than the simultaneous administration of aspirin and IA in inhibiting ADP-induced aggregation with IC50 values of 0.15 mmol/L and 0.14 mmol/L, respectively. The results suggest these IA hybrids are good candidates for multi-target therapies, and especially, may be considered as promising ADP agonists. (C) 2013 Fei-Hua Wu and Jing-Yu Liang. Published by Elsevier B.V. on behalf of Chinese Chemical Society. All rights reserved.
The first examples of ilexgenin A hybrids as a new class of multi-potent, anti-platelet agents
摘要:
Seventeen novel ilexgenin A hybrids (IA-aspirin) and (IA-NO), as donor hybrids (IA-NO will release NO in vivo and function as NO donor), were designed and synthesized in order to develop new multi-targeting agents for the treatment of platelet disorders. Their in vitro activities against ADP, AA and thrombin were evaluated. As a result, IA hybrids achieved substantial increases in the three tested pathways compared with IA. Encouragingly, the most potent hybrid compounds 6d and 14d displayed about 8-fold higher potency than aspirin, and 3-fold higher potency than the simultaneous administration of aspirin and IA in inhibiting ADP-induced aggregation with IC50 values of 0.15 mmol/L and 0.14 mmol/L, respectively. The results suggest these IA hybrids are good candidates for multi-target therapies, and especially, may be considered as promising ADP agonists. (C) 2013 Fei-Hua Wu and Jing-Yu Liang. Published by Elsevier B.V. on behalf of Chinese Chemical Society. All rights reserved.
Evaluation of nitrate-substituted pseudocholine esters of aspirin as potential nitro-aspirins
作者:John F. Gilmer、Louise M. Moriarty、John M. Clancy
DOI:10.1016/j.bmcl.2007.03.009
日期:2007.6
compounds potentially capable of releasing both aspirin and nitric oxide in vivo. A series of nitrate-bearing alkyl esters of aspirin were prepared based on the choline ester template preferred by human plasma butyrylcholinesterase. The degradation kinetics of the compounds were followed in human plasma solution. All compounds underwent hydrolysis rapidly (t(1/2) approximately 1min) but generating
Antiinflammatory, Gastrosparing, and Antiplatelet Properties of New NO-Donor Esters of Aspirin
作者:Clara Cena、Marco L. Lolli、Loretta Lazzarato、Elena Guaita、Giuseppina Morini、Gabriella Coruzzi、Stuart P. McElroy、Ian L. Megson、Roberta Fruttero、Alberto Gasco
DOI:10.1021/jm020969t
日期:2003.2.1
aspirin is joined by an ester linkage to furoxan moieties, with different ability to release NO, were synthesized and tested for NO-releasing, antiinflammatory, antiaggregatory, and ulcerogenic properties. Related furazan derivatives, aspirin, its propyl ester, and its gamma-nitrooxypropyl ester were taken as references. All the products described present an antiinflammatory trend, maximized in derivatives
Synthesis and in vitro evaluation of triphenylphosphonium derivatives of acetylsalicylic and salicylic acids: structure-dependent interactions with cancer cells, bacteria, and mitochondria
作者:Olga V. Tsepaeva、Taliya I. Salikhova、Leysan R. Grigor’eva、Denis V. Ponomaryov、Trinh Dang、Rezeda A. Ishkaeva、Timur I. Abdullin、Andrey V. Nemtarev、Vladimir F. Mironov